DE69316067T2 - Arzneimittel zur Verwendung bei der Behandlung von Parkinsonismus - Google Patents

Arzneimittel zur Verwendung bei der Behandlung von Parkinsonismus

Info

Publication number
DE69316067T2
DE69316067T2 DE69316067T DE69316067T DE69316067T2 DE 69316067 T2 DE69316067 T2 DE 69316067T2 DE 69316067 T DE69316067 T DE 69316067T DE 69316067 T DE69316067 T DE 69316067T DE 69316067 T2 DE69316067 T2 DE 69316067T2
Authority
DE
Germany
Prior art keywords
group
carbon atoms
treatment
aryl
heterocyclic group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69316067T
Other languages
English (en)
Other versions
DE69316067D1 (de
Inventor
Fumio Suzuki
Junichi Shimada
Akio Ishii
Shunji Ichikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of DE69316067D1 publication Critical patent/DE69316067D1/de
Publication of DE69316067T2 publication Critical patent/DE69316067T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69316067T 1992-04-08 1993-04-08 Arzneimittel zur Verwendung bei der Behandlung von Parkinsonismus Expired - Lifetime DE69316067T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8711592 1992-04-08

Publications (2)

Publication Number Publication Date
DE69316067D1 DE69316067D1 (de) 1998-02-12
DE69316067T2 true DE69316067T2 (de) 1998-07-02

Family

ID=13905960

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69316067T Expired - Lifetime DE69316067T2 (de) 1992-04-08 1993-04-08 Arzneimittel zur Verwendung bei der Behandlung von Parkinsonismus

Country Status (11)

Country Link
EP (1) EP0565377B1 (de)
JP (1) JP2613352B2 (de)
AT (1) ATE161723T1 (de)
BR (1) BR1100636A (de)
CA (1) CA2093403C (de)
DE (1) DE69316067T2 (de)
DK (1) DK0565377T3 (de)
ES (1) ES2112386T3 (de)
GR (1) GR3026233T3 (de)
HK (1) HK1001835A1 (de)
NO (1) NO303265B1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2106771C (en) * 1992-02-19 2004-11-02 Yukio Ishida Highly water absorbed rice, method for producing same and application of same
JP2928386B2 (ja) * 1992-07-08 1999-08-03 協和醗酵工業株式会社 うつ病治療剤
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
ZA945609B (en) * 1993-07-28 1995-05-12 Rhone Poulenc Rorer Ltd [Di(ether or thioether)heteroaryl or fluoro substituted aryl] compounds
US5703085A (en) * 1994-02-23 1997-12-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
WO1998005334A1 (en) * 1996-08-07 1998-02-12 Kyowa Hakko Kogyo Co., Ltd. Fat emulsion containing xanthine derivative
ATE325610T1 (de) 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
EP2336133A1 (de) 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purinanaloga mit HSP90-inhibierender Wirkung
WO2004096228A1 (en) 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
CA2554426C (en) 2004-01-28 2012-10-16 Kyowa Hakko Kogyo Co., Ltd. Agents for treating migraine
EP1869027A4 (de) 2005-03-30 2010-06-23 Conforma Therapeutics Corp Alkynyl-pyrrolopyrimidine und entsprechende analoga als hsp90-hemmer
CA2608111A1 (en) * 2005-04-22 2006-11-02 Novacardia, Inc. Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions
MX2009006346A (es) * 2006-12-22 2010-03-03 Sanol Arznei Schwarz Gmbh Derivados de 8-etinilxantina como antagonistas de receptores de a2a selectivos.
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
WO2020125779A1 (en) * 2018-12-21 2020-06-25 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
WO2020216152A1 (en) * 2019-04-24 2020-10-29 Dongguan Hec New Drug R&D Co., Ltd. 8-substituted aryl vinyl xanthine derivatives and uses thereof
CN110041331B (zh) * 2019-05-17 2020-08-07 广东东阳光药业有限公司 苯乙烯基黄嘌呤衍生物及其用途
CN112409360B (zh) * 2019-08-22 2022-12-23 广东东阳光药业有限公司 杂芳基乙烯基黄嘌呤衍生物及其用途
CN112300165B (zh) * 2019-11-11 2022-03-04 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111018856B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111072663B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7011094A (de) * 1969-07-30 1971-02-02
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
WO1992006976A1 (fr) * 1990-10-18 1992-04-30 Kyowa Hakko Kogyo Co., Ltd. Derive de xanthine

Also Published As

Publication number Publication date
EP0565377A1 (de) 1993-10-13
JP2613352B2 (ja) 1997-05-28
GR3026233T3 (en) 1998-05-29
JPH0616559A (ja) 1994-01-25
CA2093403C (en) 1999-08-10
HK1001835A1 (en) 1998-07-10
CA2093403A1 (en) 1993-10-09
EP0565377B1 (de) 1998-01-07
ES2112386T3 (es) 1998-04-01
ATE161723T1 (de) 1998-01-15
NO931317D0 (no) 1993-04-06
DK0565377T3 (da) 1998-03-16
NO931317L (no) 1993-10-11
DE69316067D1 (de) 1998-02-12
BR1100636A (pt) 2000-04-18
NO303265B1 (no) 1998-06-22

Similar Documents

Publication Publication Date Title
DE69316067D1 (de) Arzneimittel zur Verwendung bei der Behandlung von Parkinsonismus
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
EE03139B1 (et) Piperasiiniderivaadid, nende kasutamine ja farmatseutiline kompositsioon
HUP0102295A2 (hu) Citokinek által közvetített betegségek kezelésére alkalmas benzamid-származékok
DE60017115D1 (de) Amid-derivate und deren medizinische verwendung
NO179695C (no) Anvendelse av æomega-[4-(2-pyrimidinyl)-1-piperazinylÅalkylå-1H-azol-derivater for fremstilling av medisinske produkter beregnet til behandling av forstyrrelser i kognitive funksjoner
DE69112989D1 (de) Aminocoumaranderivate, ihre Herstellung und Verwendung.
ATE216584T1 (de) Xanthine-derivate als antidepressiva
ATE34976T1 (de) Arylcyclobutylalkylamine und ihre verwendung als antidepressive arzneimittel.
ATE270268T1 (de) 2,4-diamino-3-hydroxycarboxylsäurederivate als proteasome inhibitoren
ATE188212T1 (de) 2-pyrazinylethylamin-derivate und ihre verwendung als arzneimittel.
DE69110217D1 (de) Derivate der Kaffeinsäure und sie enthaltende pharmazeutische Zusammensetzungen.
ATE139441T1 (de) Verwendung von 2-iminothiazolidin-4-onderivaten als neuartige arzneimittelwirkstoffe
ATE79752T1 (de) Verwendung von chromanderivaten zur herstellung eines medikamentes zur behandlung von depressiven zustaenden.
IE800900L (en) Pyrrolidinyl-benzoic acid derivatives.
ES2054460T3 (es) Unos derivados de la ((1-arilpirrolidin-2-il)-metil)-piperazina, su preparacion y su aplicacion en terapeutica.
KR910006251A (ko) 3-이속사졸론 유도체, 그의 제조방법 및 그의 치료적 용도

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: KYOWA HAKKO KIRIN CO., LTD., TOKYO, JP